IRF1 and neoplasm: Others have used imaging mass cytometry (IMC) with a 25-antibody panel to identify tumor and immune cell markers in melanoma patients treated with immune checkpoint blockers, revealing significant associations of MHC-I, CSF1R, IRF1, LAG-3, PD-1, MHC-II and beta2-microglobulin expression in tumor tissue with progression-free survival, whereas high levels of TIM-3 and PD-L2 in the stroma also predicted response to immunotherapy (52).